Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2025 08:30 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio® (pegunigalsidase alfa) for Fabry Disease

PARMA, Italy and WOODBRIDGE, Ontario, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for...
November 03, 2025 16:30 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have...
October 17, 2025 06:58 ET | Source: Chiesi Global Rare Diseases; Protalix Biotherapeutics

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

PARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for...
September 22, 2025 08:00 ET | Source: Chiesi Global Rare Diseases

Idebenone Accepted by FDA for Priority Review for Leber Hereditary Optic Neuropathy (LHON)

FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing approved treatments in the U.S.; action date of February 28, 2026 ...
September 09, 2025 11:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

Results presented focus on clinical insights on Fabry disease and alpha-mannosidosis Additional presentations showcase patient-reported journeys and outcomes PARMA, Italy, Sept. 09, 2025 (GLOBE...
September 09, 2025 11:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

Results presented focus on clinical insights on Fabry disease and alpha-mannosidosis Additional presentations showcase patient-reported journeys and outcomes PARMA, Italy, Sept. 09, 2025 (GLOBE...
July 28, 2025 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Spotlights the Profound Impact of Epidermolysis Bullosa in the Film “Living Between Pain and Hope” as part of “The Next Frontier,” a New Series Presented by the Biotechnology Innovation Organization

BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases (Chiesi) proudly shares its contribution to the thought-provoking film "Living Between Pain and Hope," as part of “The Next...
June 23, 2025 08:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases

PARMA, Italy, June 23, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare...
June 14, 2024 11:57 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut

• Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly • Additional presentations...
May 22, 2024 09:00 ET | Source: Chiesi Global Rare Diseases

Chiesi Global Rare Diseases Makes Debut in the Endocrinology Landscape with Multiple Presentations at the Endocrine Society’s ENDO 2024 Meeting

BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare...